Literature DB >> 22810601

Neuromyelitis optica spectrum disorders.

Dean M Wingerchuk.   

Abstract

Neuromyelitis optica is an uncommon inflammatory demyelinating CNS disorder that is distinct from multiple sclerosis with respect to clinical, laboratory, neuroimaging, and prognostic characteristics. Autoantibodies that target aquaporin-4 are highly specific for neuromyelitis optica and have helped define a spectrum of disease beyond the classic definition of acute transverse myelitis and optic neuritis. Accumulating evidence supports the pathogenic potential that these autoantibodies possess in relation to the unique vasculocentric immunopathology of the disease. Current treatment strategies therefore include the use of corticosteroids and plasmapheresis for acute attacks and general or humoral immunosuppression for attack prevention. Ongoing research will focus on establishing the pathogenic mechanisms of the disease, in part derived from newly reported animal models, and testing-focused treatment strategies that evolve from this knowledge.

Entities:  

Year:  2010        PMID: 22810601     DOI: 10.1212/01.CON.0000389937.69413.15

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  14 in total

1.  Practice current: How do you treat neuromyelitis optica?

Authors:  Aravind Ganesh
Journal:  Neurol Clin Pract       Date:  2017-04

2.  Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.

Authors:  Tanuja Chitnis; Jayne Ness; Lauren Krupp; Emmanuelle Waubant; Tyler Hunt; Cody S Olsen; Moses Rodriguez; Tim Lotze; Mark Gorman; Leslie Benson; Anita Belman; Bianca Weinstock-Guttman; Greg Aaen; Jennifer Graves; Marc Patterson; John W Rose; T Charles Casper
Journal:  Neurology       Date:  2015-12-18       Impact factor: 9.910

Review 3.  Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials.

Authors:  Sonia Labrador-Velandia; María Luz Alonso-Alonso; Sara Alvarez-Sanchez; Jorge González-Zamora; Irene Carretero-Barrio; José Carlos Pastor; Iván Fernandez-Bueno; Girish Kumar Srivastava
Journal:  World J Stem Cells       Date:  2016-11-26       Impact factor: 5.326

4.  No association of AQP4 polymorphisms with neuromyelitis optica and multiple sclerosis.

Authors:  Ting-Ting Yang; Yang He; Ya-Juan Xiang; Dong-Hui Ao; Yang-Yang Wang; Qi Zhang; Xiang-Jun He; Shan-Shan Zhong; Jian Wu; Guang-Zhi Liu
Journal:  Transl Neurosci       Date:  2016-08-22       Impact factor: 1.757

Review 5.  Location, length, and enhancement: systematic approach to differentiating intramedullary spinal cord lesions.

Authors:  Sarah Mohajeri Moghaddam; Alok A Bhatt
Journal:  Insights Imaging       Date:  2018-06-12

6.  Late Onset of Neuromyelitis Optica Spectrum Disorders.

Authors:  Yara Dadalti Fragoso; Heloisa Helena Ruocco; Ronaldo Maciel Dias; Hideraldo Cabeça; Ricardo Gonçalves; Nise A de Carvalho Sousa; Caroline Vieira Spessotto; Carlos Bernardo Tauil; Soniza Vieira Alves-Leon; Sidney Gomes; Marcus Vinicius M Gonçalves; Suzana C Nunes Machado; Andrea Anacleto; Eber Castro Correa; Maria Lucia V Pimentel; Gutemberg Augusto C Santos
Journal:  Neurol Ther       Date:  2019-07-02

Review 7.  Pediatric multiple sclerosis: current concepts and consensus definitions.

Authors:  Joaquin A Pena; Timothy E Lotze
Journal:  Autoimmune Dis       Date:  2013-11-02

Review 8.  Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms.

Authors:  Sarosh R Irani; Jeffrey M Gelfand; Adam Al-Diwani; Angela Vincent
Journal:  Ann Neurol       Date:  2014-07-10       Impact factor: 10.422

Review 9.  The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Authors:  Michalina Jasiak-Zatonska; Alicja Kalinowska-Lyszczarz; Slawomir Michalak; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2016-03-02       Impact factor: 5.923

10.  TSPO PIGA Ligands Promote Neurosteroidogenesis and Human Astrocyte Well-Being.

Authors:  Eleonora Da Pozzo; Chiara Giacomelli; Barbara Costa; Chiara Cavallini; Sabrina Taliani; Elisabetta Barresi; Federico Da Settimo; Claudia Martini
Journal:  Int J Mol Sci       Date:  2016-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.